AI Article Synopsis
Article Abstract
Immune escape is observed with SARS-CoV-2 Omicron (Pango lineage B.1.1.529), the predominant circulating strain worldwide. A booster dose was shown to restore immunity against Omicron infection; however, real-world data comparing mRNA (BNT162b2; Comirnaty) and inactivated vaccines’ (CoronaVac; Sinovac) homologous and heterologous boosting are lacking. A retrospective study was performed to compare the rate and outcome of COVID-19 in healthcare workers (HCWs) with various vaccination regimes during a territory-wide Omicron BA.2.2 outbreak in Hong Kong. During the study period from 1 February to 31 March 2022, 3167 HCWs were recruited, and 871 HCWs reported 746 and 183 episodes of significant household and non-household close contact. A total of 737 HCWs acquired COVID-19, all cases of which were all clinically mild. Time-dependent Cox regression showed that, compared with two-dose vaccination, three-dose vaccination reduced infection risk by 31.7% and 89.3% in household contact and non-household close contact, respectively. Using two-dose BNT162b2 as reference, two-dose CoronaVac recipient had significantly higher risk of being infected (HR 1.69 p < 0.0001). Three-dose BNT162b2 (HR 0.4778 p< 0.0001) and two-dose CoronaVac + BNT162b2 booster (HR 0.4862 p = 0.0157) were associated with a lower risk of infection. Three-dose CoronaVac and two-dose BNT162b2 + CoronaVac booster were not significantly different from two-dose BNT162b2. The mean time to achieve negative RT-PCR or E gene cycle threshold 31 or above was not affected by age, number of vaccine doses taken, vaccine type, and timing of the last dose. In summary, we have demonstrated a lower risk of breakthrough SARS-CoV-2 infection in HCWs given BNT162b2 as a booster after two doses of BNT162b2 or CoronaVac.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416324 | PMC |
| http://dx.doi.org/10.3390/vaccines10081322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer.
Vaccine
December 2024
Monash University, Department of Oncology, School of Clinical Sciences, Melbourne, VIC, Australia; University of Bern, Department of Clinical Research (Medicine), Bern, Switzerland; University Cancer Centre, Bern, Switzerland.
Background: The COVID-19 pandemic has significantly impacted people with cancer. Initial vaccine studies excluded patients with malignancy. Immunocompromised individuals remain vulnerable to SARS-CoV-2, necessitating detailed understanding of vaccine response.
View Article and Find Full Text PDFCOVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from -endemic villages in Mayuge District, Uganda: a cross-sectional study.
Front Public Health
December 2024
Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Article Synopsis
- The COVID-19 pandemic has had severe health and economic impacts globally, with vaccination being crucial for control, especially in regions with high rates of helminth infections, which could affect vaccine responses.
- A study in Uganda surveyed 450 individuals to assess helminth prevalence and COVID-19 vaccine responses; results showed high infection rates of schistosomiasis (36.4%) and hookworms (36.9%), with 93.14% vaccination coverage among a smaller group interviewed.
- Despite widespread vaccination, a significant portion of those vaccinated had low anti-S1 IgG antibody levels, indicating that helminth infections might reduce vaccine efficacy among individuals with moderate to heavy infections.
Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
Vaccine
December 2024
School of Health Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia; Malaysia Genome and Vaccine Institute, National Institutes of Biotechnology Malaysia, Jalan Bangi, 43000 Kajang, Selangor, Malaysia. Electronic address:
This prospective cohort study examines the long-term humoral immune responses post-COVID-19 vaccination in 146 individuals who received either a homologous three-dose BNT162b2 vaccine regimen (PPP) or two primary doses of CoronaVac followed by BNT162b2 booster (SSP) in Malaysia. The study focuses on serum anti-S1-RBD-IgG, -IgA, and -IgM, using the ELISA method. The results show that BNT162b2 outperformed CoronaVac in the two dose primary vaccination series.
View Article and Find Full Text PDFThe Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol.
Trials
November 2024
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Australia.
Article Synopsis
- COVID-19 vaccination in Australia began in February 2021, with initial vaccines requiring two doses; booster vaccinations are now being recommended to maintain immunity.
- The PICOBOO trial is a multi-site study that tests various COVID-19 booster vaccines in children and adults, looking at their effectiveness and safety across different vaccination histories and age groups.
- This adaptive trial structure allows for rapid adjustments to research elements, helping to explore the best approaches for combating COVID-19 variants and assessing new vaccines as they are introduced.
Network Analysis of Dysregulated Immune Response to COVID-19 mRNA Vaccination in Hemodialysis Patients.
Vaccines (Basel)
October 2024
Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Introduction: End-stage renal disease (ESRD) results in immune dysfunction that is characterized by both systemic inflammation and immune incompetence, leading to impaired responses to vaccination.
Methods: To unravel the complex regulatory immune interplay in ESRD, we performed the network-based transcriptomic profiling of ESRD patients on maintenance hemodialysis (HD) and matched healthy controls (HCs) who received the two-dose regimen of the COVID-19 mRNA vaccine BNT162b2.
Results: Co-expression networks based on blood transcription modules (BTMs) of genes differentially expressed between the HD and HC groups revealed co-expression patterns that were highly similar between the two groups but weaker in magnitude in the HD compared to HC subjects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!